Cytori Therapeutics Inc (NASDAQ:CYTX) rose 9.3% on Tuesday . The company traded as high as $0.46 and last traded at $0.39. Approximately 13,941 shares changed hands during mid-day trading, a decline of 96% from the average daily volume of 375,664 shares. The stock had previously closed at $0.43.

CYTX has been the topic of a number of research reports. ValuEngine upgraded Cytori Therapeutics from a “hold” rating to a “buy” rating in a report on Monday, July 2nd. HC Wainwright restated a “buy” rating and issued a $6.00 price target on shares of Cytori Therapeutics in a report on Wednesday, July 11th. Zacks Investment Research upgraded Cytori Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, July 11th. Finally, Maxim Group cut Cytori Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, August 15th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Cytori Therapeutics has a consensus rating of “Buy” and an average target price of $10.56.

The firm has a market cap of $3.13 million, a P/E ratio of -0.06 and a beta of 2.52.

Cytori Therapeutics (NASDAQ:CYTX) last announced its earnings results on Tuesday, August 14th. The biotechnology company reported ($0.59) EPS for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.09). The company had revenue of $1.56 million for the quarter, compared to analyst estimates of $2.50 million. Cytori Therapeutics had a negative net margin of 380.64% and a negative return on equity of 202.09%. On average, equities research analysts forecast that Cytori Therapeutics Inc will post -0.85 earnings per share for the current year.

Cytori Therapeutics Company Profile (NASDAQ:CYTX)

Cytori Therapeutics, Inc, a therapeutics company, together with its subsidiaries, develops regenerative and oncologic therapies from its proprietary cell therapy and nanoparticle platforms for various medical conditions. Its lead drug candidate, ATI-0918, is a generic version of pegylated liposomal encapsulated doxorubicin, which is in Phase III clinical trial and used for various cancer types.

See Also: What is dollar cost averaging (DCA)?

Receive News & Ratings for Cytori Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.